Croissy-Beaubourg and Montpellier, December 19, 2017, 6:00pm CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, eligible for PEA-PME equity savings plans) a company specialized in in vitro diagnostics and theranostics, today announced the discontinuation of its Prestizia research…
Lisa Tracker monitoring kits will be provided with the Flixabi® biosimilar Croissy-Beaubourg and Montpellier, November 14, 2017, 6:00pm CET – THERADIAG (ISIN code: FR0004197747, Ticker: ALTER) a company specialized in in vitro diagnostics and theranostics, is today…
Revenues to September 30, 2017: +7%Continuing strong growth in theranostics sales: +27%Percentage of revenues from internal products maintained: 74%Croissy-Beaubourg and Montpellier, October 26, 2017, 6:00pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, PEA-PME eligible), a company specializing…